Healthcare is growing ever more complex, and in this complexity, the laws, being restrictive in nature, produce inequitable distributions of burden, disproportionately affecting specific individuals and populations more than others.
Semaglutide and the Expansion Problem: When One Trial Becomes a Platform
Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...
Read more
